CRISPR Therapeutics develops gene editing medicines, including CASGEVY, an approved therapy for sickle cell disease and beta thalassemia. It last closed at $39.10 on Nov 20, up 0.44% on the day. The next earnings report for CRSP is expected around Thu, Feb 11, 2027, after the close. For the quarter ended Sep 2026, CRSP reported EPS of -$1.15 on revenue of $12.7M, with revenue up 1325.1% from a year ago. Over its last 8 reports the stock moved an average of 4.8% the session after earnings. Over the last 12 months CRSP insiders bought $0 of stock on the open market and sold $17.9M, according to SEC Form 4 filings.
AI Auto Pilots
Is CRSP in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CRSP.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on CRSPStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
CRSP · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 20% below its 20 day and 30% below its 50 day average. It is 34% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $38.15, and the nearest resistance the Pivot at $39.14.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 6.6%/day
Key levels
$63.4552 week high+62.3%
$55.02Swing high (Aug 12)+40.7%
$52.27200 day average+33.7%
$52.14100 day average+33.4%
$50.7150 day average+29.7%
$46.7620 day average+19.6%
$40.13Pivot R1+2.6%
$39.14Pivot+0.1%
$39.10Last close
$38.1552 week low−2.4%
$38.11Pivot S1−2.5%
Indicators
RSI (14)
27.82
Oversold below 30
Oversold
MACD
-3.37
Below its signal line
Bearish
Stochastic
4.5
Near the bottom of its range
Oversold
ADX (14)
22.2
Weak trend
Williams %R
-93.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-118.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−21.9%
Change over 10 sessions
Bearish
ATR (14)
$2.58
Typical daily range, 6.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 15.8%/day
Key levels
$63.4552 week high+62.3%
$55.02Swing high (Aug 12)+40.7%
$52.27200 day average+33.7%
$52.14100 day average+33.4%
$50.7150 day average+29.7%
$46.7620 day average+19.6%
$40.13Pivot R1+2.6%
$39.14Pivot+0.1%
$39.10Last close
$38.1552 week low−2.4%
$38.11Pivot S1−2.5%
Indicators
RSI (14)
35.72
Weak, oversold below 30
Neutral
MACD
-2.10
Below its signal line
Bearish
Stochastic
8.0
Near the bottom of its range
Oversold
ADX (14)
28.4
Trending up
Williams %R
-96.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-213.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−24.4%
Change over 10 sessions
Bearish
ATR (14)
$6.18
Typical daily range, 15.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRSP
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CRSP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow CRSP usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for CRSPHow many large options trades hit CRSP, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in CRSP in the last 90 days.
From SEC Form 4 filings by CRSP's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRSP is in one of them and how their past CRSP trades turned out.
From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data
About CRISPR Therapeutics AG
CRISPR Therapeutics is a biopharmaceutical company based in Zug, Switzerland, that develops medicines using CRISPR gene editing technology. Its approved therapy, CASGEVY, is co-developed and co-commercialized with Vertex and treats eligible patients with sickle cell disease or beta thalassemia. The company's pipeline also includes gene editing treatments for liver diseases, siRNA medicines for cardiovascular and clotting conditions, cell therapies for autoimmune diseases and cancer, and a cell-based treatment for type 1 diabetes. Its medicines target patients with serious diseases, and partners include Vertex and Eli Lilly.